SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery left internal mammary artery (LIMA) take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.
"We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region," the company wrote in a LinkedIn post. "At SS Innovations International, Inc. we remain committed to enabling hospitals and…"
The expansion comes as SS Innovations reports significant growth in installations of its SSi Mantra system. As of September 8, 238 systems have been installed, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. The company is also pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets.
This news matters because it underscores the accelerating adoption of robotic-assisted surgery in emerging and established markets. For patients, robotic cardiac surgery can offer less invasive procedures, potentially leading to smaller incisions, reduced pain, shorter hospital stays, and faster recovery times compared to traditional open-heart surgery. The launch of a dedicated cardiac program at HCG Hospital indicates growing confidence among clinicians in the SSi Mantra system for complex cardiac procedures. It also signals that hospitals in India are increasingly investing in advanced robotic technologies to enhance surgical precision and patient outcomes.
For the medical device industry, SS Innovations' progress highlights the competitive landscape of surgical robotics, where companies are striving to make systems more accessible and affordable. The expansion into 12 countries and the pursuit of regulatory approvals in the U.S. and Europe suggest that SS Innovations aims to challenge established players in the global market. If successful, this could lead to more options for hospitals and potentially drive down costs through increased competition.
Investors in SSII may view the growing installation base and geographic reach as positive indicators of the company's growth trajectory. The recent expansions into Colombia, Sri Lanka, and the Philippines demonstrate the company's ability to penetrate diverse healthcare markets. However, regulatory hurdles in the U.S. and Europe remain critical milestones to watch.
For more details, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. InvestorWire, a specialized communications platform, provides advanced wire-grade press release syndication. It is part of the Dynamic Brand Portfolio at IBN, offering services such as editorial syndication to 5,000+ outlets and social media distribution. For more information, visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
